Non-melanoma skin cancer refers to a group of cancers that slowly begin in the upper layers of the skin cells. The cells in the skin sometimes change and no longer grow or behave normally. These changes often may lead to a non-cancerous (benign) growth such as dermatofibromas, moles, and warts.

The two main types of non-melanoma skin cancer are:

  • Basal cell carcinoma
  • Squamous cell carcinomas

Most skin cancers are caused by exposure to the sun. This may be long term exposure, or short periods of intense sun exposure and burning.  Because non-melanoma skin cancers are easy to treat and cure, they are often not included in cancer statistic databases.

This report provides the current incident population for non-melanoma skin cancer across 27 Major Markets (USA, France, Canada, Germany, Italy, Spain, Brazil, Mexico, Argentina, Turkey, India, UK, Netherlands, Belgium, Switzerland, Austria, Denmark, Sweden, Norway, Finland, Russia, Poland, Australia, Ireland, Japan, Korea and China) split by gender and 5-year age cohort. Including the current incident population, the report also contains information on disease background such as disease overview, risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value- added level of insight from the analysis team at Black Swan, key symptoms and co-morbidities of non-melanoma skin cancer have been quantified and presented alongside the overall incident figures. These sub populations within the main disease background are also included at country level across the 10-year forecast period (2020-2030).

The following risk factors have been linked with non-melanoma skin cancer development, although more research is needed to clarify the following risk factors in non-melanoma skin cancer:

  • Human papilloma virus infection
  • Taking medicines that make your skin more sensitive to the sun (photosensitizing drugs)
  • Smoking tobacco

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global non-melanoma skin cancer market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of non-melanoma skin cancer and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on non-melanoma skin cancer incident populations
  • Identify sub-populations within non-melanoma skin cancer which require treatment.
  • Gain an understanding of the specific markets that have the largest number of non-melanoma skin cancer patients.